More from Renaissance Capital

Cancer Genetics postpones $48 million US IPO

By Renaissance Capital,  May 17, 2012, 06:10:18 PM EDT

Cancer Genetics, which offers personalized genomic tests to improve the diagnosis and treatment of cancer, postponed its IPO on Thursday. The Rutherford, NJ-based company was founded in 1999 and booked $3 million in sales for the 12 months ended 3/31/2012. William Blair and Baird were set to be the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: News Headlines, IPOs

Referenced Stocks: CGIX



Latest News Video



Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.495 0.07  0.48%
WCRX $ 19.695 0.49  2.52%
CSCO $ 23.891 0.35  1.44%
RAD $ 2.94 0.15  5.38%
FB $ 25.789 0.46  1.76%
MSFT $ 34.8942 0.02  0.07%
F $ 15.125 0.05  0.30%
YHOO $ 26.5899 0.07  0.26%